Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.990
+0.100 (3.46%)
Nov 4, 2024, 4:00 PM EST - Market closed
BDTX Employees
Black Diamond Therapeutics had 54 employees as of December 31, 2023. The number of employees decreased by 11 or -16.92% compared to the previous year.
Employees
54
Change (1Y)
-11
Growth (1Y)
-16.92%
Revenue / Employee
n/a
Profits / Employee
-$1,491,648
Market Cap
168.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 54 | -11 | -16.92% |
| Dec 31, 2022 | 65 | -21 | -24.42% |
| Dec 31, 2021 | 86 | 17 | 24.64% |
| Dec 31, 2020 | 69 | 37 | 115.63% |
| Dec 31, 2019 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| The Joint | 794 |
| BrainsWay | 134 |
| Stereotaxis | 122 |
| Candel Therapeutics | 42 |
| Cardiff Oncology | 32 |
| Skye Bioscience | 11 |
| Sagimet Biosciences | 10 |
| Greenwich LifeSciences | 7 |
BDTX News
- 3 days ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data - Seeking Alpha
- 4 weeks ago - Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway - GlobeNewsWire
- 6 weeks ago - Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations - GlobeNewsWire
- 6 weeks ago - Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - GlobeNewsWire
- 7 weeks ago - Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive - Seeking Alpha